<p><strong>Professor Michaela Rumlová, head of a research group of the National Institute of Virology and Bacteriology at UCT Prague (and Vice-Rector for doctoral studies), holder of a licensed patent &nbsp;for antiretroviral testing assays, and recipient of the Czech Science Foundation’s President’s Award for HIV research, has also become the principal investigator of the bilateral INTER-EXCELLENCE II project “</strong><i><strong>Cellular factors regulating the export and packaging of unspliced ​​retroviral RNA</strong></i><strong>”, starting this year. In this interview, she explains how retroviruses such as HIV “hack” the cell in order to export their own genome from the nucleus into the cytoplasm, and then to the site where it is specifically packaged into nascent viral particles, a key step in viral replication. Her team is collaborating with the NIH (National Institutes of Health) and Rockefeller University to elucidate mechanisms that may help reveal new vulnerable points in the retrovirus replication cycle while simultaneously clarifying related cellular processes.</strong></p><h5><strong>Could you describe your project and its main objectives?</strong></h5><p>Retroviruses, such as HIV, are viruses that carry genetic information in the form of RNA; however, after entering a cell, they are able to reverse transcribe it into DNA and integrate it into the host genome. In order to replicate, they must transport their genetic information—in the form of unspliced RNA—from the nucleus into the cytosol. There, it serves both as a template for the production of viral proteins and as the genome of new viral particles. This is highly unusual, as the cell very carefully controls which RNA molecules are allowed to leave the nucleus. Normal protein-coding cellular RNAs, known as messenger RNAs (mRNAs), must undergo splicing—a processing step in which certain segments are removed—before being exported. When this process fails, mRNA that retains these segments is held back in the nucleus as part of quality control and subsequently degraded. Retroviruses have managed to outwit this cellular control machinery, allowing their unspliced RNA to pass into the cytoplasm.</p><p>Our project focuses on identifying the cellular proteins that assist retroviruses in this step and on the mechanism by which protein complexes bound to viral RNA are remodelled during RNA transport. The goal is to understand how the virus uses cellular mechanisms to its advantage and how this pathway is linked to the subsequent fate of the RNA, i.e. to its translation and packaging into new viral particles.</p><h5><strong>Why is this export of unspliced ​​RNA so important for retroviral replication?</strong></h5><p>Because this RNA has a dual role for the virus. On the one hand, it serves as a template for synthesizing viral proteins in the cytoplasm; on the other, it represents the genetic material itself, which must be packaged into new viral particles. The virus must package its RNA genome in its unspliced form, as only this RNA contains essential sequences without which further viral replication would be impossible.</p><p><strong>Simply put: </strong>the virus needs to get a complete copy of its genetic instructions out of the nucleus. Once the viral RNA is in the cytoplasm, it can be used as a template for synthesizing viral proteins; and a portion of these RNA molecules is then selected and packaged into a new particle as a genome. We are interested in how the virus forces the cell to allow viral RNA that is, from the cell’s perspective, “unfinished,” that is unspliced, to leave the nucleus. We are also investigating how the cell and the virus together - albeit unintentionally from the cell’s perspective - determine which RNA molecule will be translated into proteins and which will be packaged as the genome. This is one of the key, yet still not fully understood, steps of retroviral replication.</p><h5><strong>What do you think it was about your project that impressed the Ministry of Education, Youth and Sports’ jury the most?</strong></h5><p>I believe the decisive factor was a combination of several elements. First, the reviewers were primarily interested in the scientific problem itself. We are investigating a mechanism that is essential for retroviruses, but still not sufficiently understood, which may also have broader implications for the regulation of cellular processes. In addition, the quality of the team, our strong collaboration with the<strong> NIH </strong>and <strong>Rockefeller University</strong>, and the use of modern methods that will allow us to track viral RNA in great detail also played a role. It was also important that the project has clear objectives and a realistic plan.</p><h5><strong>How will this research contribute to the development of new treatments for retroviral infections?</strong></h5><p>It is important to say that this is primarily basic research. Rather than developing a new drug directly, we are trying to understand, at the molecular level, the step that the virus cannot do without. Only when we fully understand the mechanism of these cellular processes and identify the essential factors for the export of unspliced ​​RNA and how they function, will we be able to better determine which interactions or mechanisms represent potentially vulnerable points. Similar mechanisms associated with the export of unspliced ​​mRNA also appear in some diseases, such as cancer, so I &nbsp;see the benefit of our research mainly in that it will refine our understanding of these pathological processes in the cell, and retroviruses help us do so. Therefore, our work on retroviruses not only shows us how the virus works, but also how the cell itself works.</p><h5><strong>What responsibilities does your UCT Prague team have? How does the collaboration with your American partners work?</strong></h5><p>At UCT Prague, we are conducting the project’s primary experimental work. Our research involves cell cultures, viral models, and various biochemical techniques ranging from immunochemistry to microscopy that allow us to track viral RNA and identify its cellular partners. In collaboration with colleagues from <strong>NIH, Frederick</strong>, we are developing single-particle tracking methods to observe viral RNA movement in living cells across both space and time. Furthermore, we are working with colleagues from <strong>Rockefeller University to employ iCLIP </strong>methods for the precise mapping of protein-binding sites on RNA. Both collaborations are valuable to us, because they are not just about data sharing, but also about the transfer of expertise and detailed know-how.</p><h5><strong>Who else is collaborating on the project?</strong></h5><p>At UCT Prague, we collaborate closely with the Department of Biotechnology and the Department of Biochemistry and Microbiology. Externally, we work with colleagues from the Institute of<strong> Organic Chemistry and Biochemistry of the CAS (IOCB Prague)</strong> and the <strong>Central European Institute of Technology in Brno (CEITEC)</strong>. Our research naturally necessitates the integration of diverse fields of expertise; it requires combining virology, cell biology, and biochemistry with advanced imaging and modern approaches to study RNA-protein interactions. This is exactly what makes our project capable of addressing complex questions that a single laboratory cannot tackle on its own.</p><h5><strong>Are there plans to continue the project? Have you brought on new collaborators, and are you looking to welcome new colleagues to the team?</strong></h5><p>Yes, definitely. In basic research, it often happens that one answered question opens up several more. High-quality, properly interpreted data provide a foundation you can build on — and that is what moves scientists forward. It is already clear that the topic of retroviral RNA export and packaging has broader implications and may reveal more general principles of how RNA functions within the cell. We also hope the project will be attractive to students, as it connects classical molecular biology, biochemistry, and virology with cutting-edge biotechnological methods. Students are already involved in the project as part of their bachelor’s and master’s theses.</p><h5><strong>What was the personal turning point that motivated you to pursue a long-term investigation into retroviral particles?</strong></h5><p>I first encountered retroviruses in the early 1990s during my diploma thesis, when I was working at IOCB Prague on HIV-1 protease inhibitors. At that time, AIDS could not yet be effectively treated, and retrovirus research had a completely different dimension. From the very beginning, I was fascinated by how such a relatively small and simple virus can outsmart evolutionarily highly optimized cellular processes and turn them to its own advantage. And that has never stopped fascinating me. From a scientific point of view, retroviruses are remarkable; just consider one of their enzymes, reverse transcriptase, without which no diagnostic or research laboratory in the world could function today. Without it, it would be impossible to diagnose RNA viruses like SARS-CoV-2, influenza, or HIV using RT-PCR tests, or, for example to produce recombinant human proteins in bacterial cells.</p>

Tracking unspliced RNA: Professor Rumlová studies how retroviruses “hack” cells

News from LabRulezLCMS Library - Week 20, 2026

<p><strong>🎤Lindsay Repka&nbsp;</strong></p><p><strong>Lindsay Repka is a chemistry professor at Middlebury College whose research explores photoredox chemistry, catalyst stability, and visible-light-driven transformations. Her lab emphasizes both mechanistic insight and hands-on student training in advanced analytical instrumentation.</strong></p><p>In this episode of Concentrating on Chromatography, we sit down with Lindsay Repka to discuss how LC-MS and GC-MS transformed her lab’s approach to photoredox chemistry.</p><p>What began as a project to develop a visible-light photocrosslinking handle unexpectedly led to a major discovery: the solvent (DMF) was reacting with the photocatalyst itself. Using high-resolution LC-MS, Lindsay’s team observed multiple solvent adducts forming — sometimes with complete catalyst consumption. That discovery reshaped their research direction.</p><p>This episode is a rare deep dive into both LC-MS and GC-MS within the same research project, showing how chromatography-driven insight can turn unexpected degradation into productive new reactivity.</p><p><strong>If you work in:</strong></p><ul><li>Photoredox chemistry</li><li>Reaction optimization</li><li>Mass spectrometry method development</li><li>Catalyst screening</li><li>Academic synthetic chemistry</li></ul><p>…this conversation will resonate.</p><h4><strong>Key Topics Covered</strong></h4><ul><li>Photocatalyst stability in DMF, DCE, and MeCN</li><li>Demethylation under mild visible-light conditions</li><li>High-resolution Q-TOF LC-MS quantitation</li><li>Internal standard methodology in GC-MS</li><li>Signal-to-noise improvement using extracted ion chromatograms</li><li>Reaction reproducibility and quality control strategy</li></ul><h3><strong>Video Transcription</strong></h3><p>In this interview, Lindsay Repka discusses the role of photoredox chemistry in method development, photocrosslinking, solvent activation, catalyst stability, and the use of LC-MS and GC-MS to understand reaction pathways.</p><h4><strong>What is photoredox chemistry?</strong></h4><p>Photoredox chemistry uses light to activate a photocatalyst, which can either donate or accept an electron from a substrate. This generates radical species that can undergo new types of reactivity.</p><p>Repka explains that one of the key advantages of photoredox chemistry is its ability to operate under mild conditions, often using visible light. This makes it attractive for sensitive molecules and biological systems, including potential applications in drug release, live-cell chemistry, and drug development.</p><h4><strong>Photocrosslinking and drug-target interactions</strong></h4><p>Repka’s group initially aimed to develop visible-light photocrosslinking methods to study drug interactions with biological targets. Photocrosslinking can covalently link a drug to its target, making it easier to identify the biological target of a compound.</p><p>Traditional photocrosslinking often uses UV light, but visible light offers milder and more biologically compatible conditions.</p><h4><strong>From photocrosslinking to solvent activation</strong></h4><p>The project shifted direction when the desired photocrosslinking reactions gave very low yields. Instead of reacting with amino acids as intended, the radical intermediate mainly reacted with itself.</p><p>The team explored different solvents to stabilize the radical, but found that some solvents, such as DMF, were not inert. Instead, the solvent reacted with the photocatalyst or radical species, revealing unexpected solvent activation chemistry.</p><h4><strong>Why LC-MS was critical</strong></h4><p>LC-MS became essential because the reaction mixtures were too complex and low-yielding for NMR or GC-MS. High-resolution LC-MS allowed the team to detect minor products, identify photocatalyst modifications, and observe solvent addition products with high confidence.</p><p>Repka emphasizes that LC-MS was both a qualitative and quantitative tool. It was used quantitatively to measure how much photocatalyst remained after light exposure, and qualitatively to identify degradation products and new reactivity pathways.</p><h4><strong>Photocatalyst stability workflow</strong></h4><p>The team developed a systematic workflow to evaluate photocatalyst stability under light exposure. Because catalyst degradation was time-sensitive, reproducibility required strict control of experimental conditions.</p><p>Key steps included using a glove box, commercial deoxygenated solvents, accurate weighing on a microbalance, controlled light exposure in a photoreactor, and temperature control with a chiller. These precautions helped reduce day-to-day variability and enabled reproducible measurements of catalyst remaining.</p><h4><strong>Quantifying catalyst remaining by LC-MS</strong></h4><p>Calibration curves were prepared using pure photocatalyst solutions and LC-MS ion areas. The team worked in the nanomolar range to maintain linearity.</p><p>Instead of relying only on total ion chromatograms, they used extracted ion chromatograms (EICs) to improve signal-to-noise for the photocatalyst signal. Baseline subtraction was also applied to reduce noise and improve quantitation at low concentrations.</p><p>Calibration curves and quality control samples were prepared and measured on the same day as the reaction samples, because LC-MS signal intensity can vary significantly from day to day.</p><h4><strong>Why GC-MS was used later</strong></h4><p>For demethylation studies, the group moved to GC-MS because the substrates and products were small and volatile enough for gas chromatography. GC-MS was better suited for rapidly screening many reaction conditions, including different photocatalysts, solvents, and oxidants.</p><p>Instead of generating full calibration curves for every experiment, the team used an internal standard to streamline analysis and determine percent conversion based on relative response factors.</p><h4><strong>Practical lessons from the project</strong></h4><p>Repka highlights the importance of careful sample preparation, especially when working with very small quantities of photocatalysts. A high-quality microbalance, stable granite platform, antistatic tools, and aluminum weigh boats improved weighing accuracy and reproducibility.</p><p>She also argues that mass spectrometry should be a standard part of photoredox method development because it can reveal minor products, support reaction optimization, and provide insights that may be difficult or impossible to obtain by NMR alone.</p><h4><strong>Final perspective</strong></h4><p>Beyond the chemistry, Repka emphasizes the importance of student training and mentoring. For her, research is not only about discovering new reactivity but also about giving students practical experience, helping them develop independence, and preparing them for future scientific careers.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

Using LC-MS & GC-MS to Decode Photoredox Catalyst Stability

Article

Application

Video

Scientists

Interview

Science and research

The University of Chemistry and Technology, Prague is a natural centre of first-rate study and research in the area of chemistry in Czechia and is one of the country's largest educational and research institutions focused on technical chemistry, chemical and biochemical technologies, material and chemical engineering, food chemistry, and environmental studies.

UCT Prague

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

The Analytical Scientist

Agilent Technologies

Technology Networks

Thermo Fisher Scientific

C&EN

SCIEX

Waters Corporation

<p><strong>Ion Mobility (IM) advancements in Software, Data Bases, AI and Machine learning are quickly improving capabilities to make unknown identifications, separate and ID isomers, as well as improve workflows associated with metabolomics, lipidomics, PFAS, and qual-quant screening.</strong></p>
<p>In addition, IM measurements are significantly improved with HRdm High Resolution Demultiplexing.  This is the first commercial IM instrument to enable the simultaneous combination of high drift resolution, while at the same time achieving all four of the following measurement capabilities: broad mass range in a single injection, multiplexing to increase sensitivity, compatibility with fast chromatographic acquisition rates , and highest precision in CCS measurements. For more accurate CCS predictions, the better precision in the CCS training set improves AI machine learning SW. This can significantly reduce the number of potential candidate structures to select from when making unknown identifications.</p>
<blockquote>
<p><strong>Presenter:</strong> Blaine Roberts, PhD (Associate Professor, Department of Biochemistry and Department of Neurology, Emory University)</p>
</blockquote>
<blockquote>
<p>Dr. Blaine Roberts is an Associate Professor In the Department of Biochemistry and Department of Neurology at Emory University. He obtained his Bachelor of Science in Chemistry at Montana State University and his PhD in Biochemistry and Biophysics from Oregon State University. His research group focuses on using protein biochemistry and mass spectrometry to understand Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis. He has interest in understanding the role of metals in biology and has developed new proteomic technologies to measure metalloproteins. Further, his group is using proteomics to characterize new blood borne biomarkers for Alzheimer’s and Parkinson’s disease.</p>
</blockquote>


Agilent Technologies: The Hidden Pathophysiology of Lipids and Proteins in Alzheimer’s Revealed with Ion Mobility MS and Quantitative QQQ Biomarker Assays

The Hidden Pathophysiology of Lipids and Proteins in Alzheimer’s Revealed with Ion Mobility MS and Quantitative QQQ Biomarker Assays

The Hidden Pathophysiology of Lipids and Proteins in Alzheimer’s Revealed with Ion Mobility MS and Quantitative QQQ Biomarker Assays.

Pathophysiology of Lipids and Proteins in Alzheimer’s

<p><strong>Ion Mobility (IM) advancements in Software, Data Bases, AI and Machine learning are quickly improving capabilities to make unknown identifications, separate and ID isomers, as well as improve workflows associated with metabolomics, lipidomics, PFAS, and qual-quant screening.</strong></p>
<p>In addition, IM measurements are significantly improved with HRdm High Resolution Demultiplexing.  This is the first commercial IM instrument to enable the simultaneous combination of high drift resolution, while at the same time achieving all four of the following measurement capabilities: broad mass range in a single injection, multiplexing to increase sensitivity, compatibility with fast chromatographic acquisition rates , and highest precision in CCS measurements. For more accurate CCS predictions, the better precision in the CCS training set improves AI machine learning SW. This can significantly reduce the number of potential candidate structures to select from when making unknown identifications.</p>
<blockquote>
<p><strong>Presenter:</strong> Brock Juliano (Ph.D. student, Brandon Ruotolo lab, Dept of Chemistry, Univ of Michigan)</p>
</blockquote>


Agilent Technologies: Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening of Protein and Oligonucleotide Biotherapeutics.

Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening of Protein and Oligonucleotide Biotherapeutics.

Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening.

RapidFire Native MS of Proteins and Oligonucleotides

<p><strong>Welcome to The Analytical Scientist’s Trends and Challenges in PFAS Analysis forum!</strong></p>
<p>Per- and poly-fluorinated alkyl substances, or PFAS, are a family of synthetic substances used in everyday products, such as stain and grease-repellent coatings and have appeared in almost all foods and drinking water. Toxic at extremely low levels, regulators demand low detection limits, and the list of PFAS compounds under investigation continues to expand. </p>
<p>We recently asked our readers for their thoughts on the challenges involved in PFAS analysis, whether current methods are up to the task, and what analytical advances may be on the horizon. </p>
<p>Here, our panel of experts will discuss the survey findings and share their perspectives on the latest trends and best practices in PFAS analysis. </p>
<p>The event will have three parts: </p>
<ul>
<li><p><strong>Part I: A discussion of the results of our recent vendor-neutral audience survey (10-15 minutes).</strong></p>
</li>
<li><p><strong>Part II: Technology/application-focused presentations from each of our speakers (15 minutes each).</strong></p>
</li>
<li><p><strong>Part III: A chance for you to ask our speakers questions as part of an audience Q&amp;A (15 minutes).</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Day Powell (Environmental Application Specialist , Agilent)</p>
</blockquote>
<blockquote>
<p>Day has worked for Agilent as an Environmental Specialist for one year. Before this he worked for a major UK Water company (United Utilities) as a senior analyst responsible for developing new methodologies for both LC/MS and GC/MS applications.</p>
</blockquote>
<blockquote>
<p>Day has analysed PFAS for several years and helped United Utilities to gain UKAS accreditation for determining 47 PFAS by LC/MS in drinking water using direct injection to address the latest Drinking Water Inspectorate (DWI).</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Marcus Chadha (EMEA Applications Specialist Manager, Agilent)<br/>Dr. Marcus Chadha has worked for Agilent for seven years where he first worked as an LC/MS Field Application Specialist before moving on to being the EMEA Applications Specialist Manager in 2021.</p>
</blockquote>
<blockquote>
<p>In his roles he has collaborated with our Environmental and Food customers, developed new methods, and trained LC/TQ and LC-Q/TOF MS workflows to new and existing customers.</p>
</blockquote>
<blockquote>
<p>He now coordinates these activities using his team of GC/MS and LC/MS application specialists. Marcus is also responsible for the market specialisation activities for the environmental market across Europe.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Linx Waclaski (Product Manager for Ion Chromatography, Metrohm USA)</p>
</blockquote>
<blockquote>
<p>Linx Waclaski is the Product Manager for Ion Chromatography at Metrohm USA, in Riverview, Florida. He has years of experience in multiple chromatographic techniques, including ion chromatography, gas chromatography, liquid chromatography, and mass spectrometry, with extensive experience in R&amp;D and applications development.</p>
</blockquote>
<blockquote>
<p>His chromatography applications experience extends across environmental, food safety, and life sciences industries. He has an M.S. in Forensic Science from Duquesne University.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ruth Marfil-Vega (Senior Market Manager - Environmental, Shimadzu)</p>
</blockquote>
<blockquote>
<p>Dr. Ruth Marfil-Vega has 20 years of expertise in environmental chemistry and engineering in the US and Europe. She has worked with the EPA and the utilities industry to design and execute comprehensive solutions for addressing new environmental and water quality issues, including PFAS, regulated and unregulated DBPs, and other emerging contaminants.</p>
</blockquote>
<blockquote>
<p>Since Ruth joined Shimadzu five years ago, she has continued to work with environmental stakeholders to ensure that analytical instrumentation and workflows support their success.</p>
</blockquote>
<blockquote>
<p>She earned a BSc in Chemistry from the University of Valladolid (Spain) and a PhD in Environmental Science and Engineering from the University of Cincinnati.</p>
</blockquote>


Agilent Technologies: Trends and Challenges in PFAS Analysis

Trends and Challenges in PFAS Analysis

Survey findings and perspectives on the latest trends and best practices in PFAS analysis.

<p><strong>Live from the Lab presents a unique and exciting opportunity to learn about the new Thermo Scientific Orbitrap Astral mass spectrometer and discover how it can unleash the proteomics potential of your laboratory.</strong></p>
<p>Fitting seamlessly into our high-throughput proteomics workflow, the system offers the ability to obtain deeper protein coverage quicker and with higher sensitivity. As well as the mass spectrometer, we will also consider the key issues of sample preparation, chromatography and data analysis.</p>
<p>The event will be hosted by the Thermo Fisher Scientific factory in Bremen but will be live-streamed to locations across the whole EMEA region. The agenda will include presentations from designers of the new system, including Professor Alexander Makarov, as well as leading scientists who will present their thoughts and their data on the new instrument and it&#39;s potential for a range of scientific fields including cancer research and precision medicine.</p>
<p>In addition to the Orbitrap Astral we will showcase the complete portfolio of instruments offering the solution of an Orbitrap for every lab!</p>
<h3><strong>Agenda:</strong></h3>
<h5><strong>10:00-10:10 Welcome and introduction</strong></h5>
<ul>
<li>Thomas Moehring, Thermo Fisher Scientific</li>
</ul>
<h5><strong>10:10-10:40 Velocity- A benchmarking workflow for high throughput DIA label-free quantification</strong></h5>
<ul>
<li>Julia Kraegenbring, Thermo Fisher Scientific</li>
</ul>
<h5><strong>10:40-11:10 Rethink what’s possible with the Orbitrap™ Astral ™ Mass Spectrometer</strong></h5>
<ul>
<li>Alexander Makarov and Hamish Stewart, Thermo Fisher</li>
</ul>
<h5><strong>11:10-11:40 DIA with non-isobaric multiplexing on a novel high-resolution platform</strong></h5>
<ul>
<li>Sofia Steigerwald, Mann Lab, Max Planck Institute of Biochemistry, Institute of Biochemistry</li>
</ul>
<h5><strong>11:40-12:10 Coffee Break and Q&amp;A session</strong></h5>
<h5><strong>12:10-12:40 Plasma proteomics with unprecedented depth and scale</strong></h5>
<ul>
<li>Markus Vossman, Seer Inc.</li>
</ul>
<h5><strong>12:40-13:10 Sensitive and robust high-throughput workflow for quantitative and qualitative single cell/single cell-like analysis</strong></h5>
<ul>
<li>Bernard Delanghe, Thermo Fisher Scientific</li>
</ul>
<h5><strong>13:10-13:40 Single-cell proteomics on the Orbitrap Astral MS for the exploration of cell heterogeneity</strong></h5>
<ul>
<li>Benjamin Furtwängler, Technical University of Denmark</li>
</ul>
<h5><strong>13:40-14:30 Lunch and Q&amp;A session</strong></h5>
<h5><strong>14:30-15:30 Laboratory/ Factory Plus Tour Orbitrap Astral Show and Tell</strong></h5>
<h5><strong>15:30-17:00 Networking discussions</strong></h5>


Live from the Lab

Learn about the new Thermo Scientific Orbitrap Astral mass spectrometer and discover how it can unleash the proteomics potential of your laboratory.

<p><strong>This popular online event will once again bring together leading scientists in the field as they highlight the latest advancements in translational proteomics and metabolomics. Presentations will cover areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.</strong></p>
<p>This online symposium will explore:</p>
<ul>
<li><strong>Cutting-edge proteomics for brain aging and dementia biomarkers</strong></li>
<li><strong>Innovations in single-cell proteomics technology</strong></li>
<li><strong>Next-gen protein sequencing and PTM detection</strong></li>
<li><strong>Healthcare transformation through data analytics and remote monitoring</strong></li>
</ul>
<h3><strong>Agenda</strong></h3>
<h5><strong>16:00 – 16:40 (BST) Keynote: Transforming Healthcare Using Deep Data and Remote Monitoring</strong></h5>
<ul>
<li>Keynote Speaker: Prof. Michael Snyder</li>
</ul>
<h5>16:40 – 16:50 Networking Break</h5>
<h5><strong>16:50 – 17:35 Challenges In Human Metabolomics Studies and Standardizing Quantitative Metabolomics Globally</strong></h5>
<ul>
<li>Speakers: Prof. Jerzy Adamski &amp; Markus Langsdorf, PhD</li>
</ul>
<h5>17:35 – 17:45 Networking Break</h5>
<h5><strong>17:45 – 18:35 Proteomics as a Tool to Identify Drivers and Biomarkers of Brain Aging and Dementia</strong></h5>
<ul>
<li>Speaker: Keenan Walker, PhD</li>
</ul>
<h5>18:35 – 18:45 Networking Break</h5>
<h5><strong>18:45 – 19:05 Advancing Protein Analysis with Next-Generation Protein Sequencing™</strong></h5>
<ul>
<li>Speaker: Ben Moree, PhD</li>
</ul>
<h5>19:05 – 19:15 Networking Break</h5>
<h5><strong>19:15 – 20:05 Improved Sample Preparation, Separations and Data Acquisition for Single-Cell Proteomics</strong></h5>
<ul>
<li>Speaker: Ryan Kelly, PhD</li>
</ul>
<h5>20:05 – 20:15 Networking Break</h5>
<h5><strong>20:15 – 20:55 Identification and Analysis of Non-Invasive Biomarkers in Exhaled Breath</strong></h5>
<ul>
<li>Speaker: Tina Chou, PhD</li>
</ul>


Technology Networks: Advances in Proteomics & Metabolomics 2023

Advances in Proteomics & Metabolomics 2023 - Day1

Areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.

<p><strong>This popular online event will once again bring together leading scientists in the field as they highlight the latest advancements in translational proteomics and metabolomics. Presentations will cover areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.</strong></p>
<p>This online symposium will explore:</p>
<ul>
<li><strong>Cutting-edge proteomics for brain aging and dementia biomarkers</strong></li>
<li><strong>Innovations in single-cell proteomics technology</strong></li>
<li><strong>Next-gen protein sequencing and PTM detection</strong></li>
<li><strong>Healthcare transformation through data analytics and remote monitoring</strong></li>
</ul>
<h3><strong>Agenda</strong></h3>
<h5><strong>16:00 – 16:40 Deciphering Microbial Omics Signatures in Multidimensional Mass Spectrometry</strong></h5>
<ul>
<li>Speaker: Aivett Bilbao, PhD</li>
</ul>
<h5>16:40 – 16:50 Networking Break</h5>
<h5><strong>16:50 – 17:10 Precision Proteomics Accelerates the Early Detection of Dementia</strong></h5>
<ul>
<li>Speaker: Mariana Fontes, PhD</li>
</ul>
<h5>17:10 – 17:20 Networking Break</h5>
<h5><strong>17:20 – 18:10 Towards the Making of Molecular Movies Directed by the Circulating Proteome</strong></h5>
<ul>
<li>Speaker: Prof. Jochen Schwenk</li>
</ul>
<h5>18:10 – 18:20 Networking Break</h5>
<h5><strong>18:20 – 18:40 Lipidomic Variabilities of Human Blood Plasma</strong></h5>
<ul>
<li>Speaker: Prof. Markus Wenk</li>
</ul>
<h5>18:40 – 18:50 Networking Break</h5>
<h5><strong>18:50 – 19:30 The SEISMIC Facility for Spatially Resolved Single and Sub-Cellular Omics</strong></h5>
<ul>
<li>Speaker: Prof. Melanie Bailey</li>
</ul>


Advances in Proteomics & Metabolomics 2023 - Day 2

<p><strong>Glycosylation plays a crucial role in determining the pharmacological properties of biotherapeutics. The molecular heterogeneity of glycosylated biotherapeutics makes it difficult to provide thorough characterization of intact glycoproteins by mass spectrometry.</strong></p>
<p>Current methods for analyzing biotherapeutics only measure fragments of the compound or rely on partial digestion of the glycans to reduce sample complexity. These limitations pose important risks and challenges for biotechnology companies that need to report human-compatible and consistent glycosylation, critical for drug safety and efficacy.  </p>
<p>We will present a new approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment and offers insights into glycoform composition when coupled with a suitable bioinformatic strategy. In addition, we highlight the application of charge detection native mass spectrometry (Direct Mass Technology mode) towards the elucidation of masses and aggregation of heterogeneous glycosylated biotherapeutics. </p>
<p>Key Learning Objectives:</p>
<ul>
<li><p><strong>How to elucidate masses from heterogeneous glycosylated biotherapeutics</strong> </p>
</li>
<li><p><strong>Learn how proton transfer charge reduction (PTCR) can simplify complex protein mixtures</strong> </p>
</li>
<li><p><strong>Learn when to use PTCR based methods compared to Direct Mass Technology mode for analysis of biotherapeutics</strong></p>
</li>
</ul>
<p>Who Should Attend:</p>
<ul>
<li><p>Laboratory Managers </p>
</li>
<li><p>Biopharmaceutical Researchers </p>
</li>
<li><p>Protein Scientists</p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Wendy Sandoval (Director, Translational Mass Spectrometry, Genentech)</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ann Thayer (Contributing Editor, C&amp;EN Media Group)</p>
</blockquote>


C&EN: Direct Analysis of Glycosylated Therapeutics

Direct Analysis of Glycosylated Therapeutics

New approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins.

<p><strong>Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces. MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”</strong></p>
<p>In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.</p>
<p>Who Should Attend: Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</p>
<h3><strong>Part Two – October 17th, 2023: Untargeted versus Targeted Imaging</strong></h3>
<p>In the second session, we will look at the differences between untargeted and targeted imaging: the systems on which the data can be acquired, what data is collected using each technique, how data can be analyzed and how they can work together to provide a complete picture.</p>
<blockquote>
<p><strong>Presenter:</strong> Anthony Midley (Principal Applications Support Scientist, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Anthony Midey is a Principal Applications Support Scientist in Waters Biomedical Research group at Americas Application Laboratory, providing pre- and post-sales support in DESI, MALDI, and imaging mass spectrometry. He is also the BMR team lead for targeted metabolomics and lipidomics LC-MSMS applications. Anthony received his Ph.D. in spectroscopy and mass spectrometry from the University of Rochester and joined Waters in 2015. He has over 55 publications in peer-reviewed journals, with over 10 years working in the analytical instruments sector.</p>
</blockquote>
<blockquote>
<p><strong>HOST:</strong> Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.</p>
</blockquote>


Waters Corporation: Untargeted versus Targeted Imaging

Untargeted versus Targeted Imaging

We will look at the differences between untargeted and targeted MS imaging.

<p><strong>Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces. MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”</strong></p>
<p>In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.</p>
<p>Who Should Attend: Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</p>
<h3><strong>Part One – October 10th, 2023: What is mass spectrometric imaging?</strong></h3>
<p>In this session, we will examine the types of MS imaging techniques on the market and the platforms on which they can be run. We will also discuss the types of data and information that MS imaging can provide and what imaging provides a user that other mass spectrometric techniques cannot.</p>
<blockquote>
<p><strong>Presenter:</strong>  Bindesh Shrestha (Senior Application Support Scientist, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Bindesh Shrestha, PhD., is an expert in the field of imaging mass spectrometry and ambient ionization. He completed his graduate work at the George Washington University and is currently employed with the Waters Corporation. In Waters, Bindesh supports academic grant efforts with biomedical applications, such as imaging MS and metabolomics. Bindesh has co-authored about three dozen peer-reviewed articles in leading journals, such as Angewandte Chemie, Analytical Chemistry, Analyst, Nature Methods. In the last two years, he edited a book on single-cell metabolism with Springer and published an introductory book on imaging mass spectrometry with Elsevier.</p>
</blockquote>
<blockquote>
<p><strong>HOST:</strong> Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.</p>
</blockquote>


Waters Corporation: What is Mass Spectrometry Imaging?

What is Mass Spectrometry Imaging?

We will examine the types of MS imaging techniques on the market and the platforms on which they can be run.

<p><strong>Are you ready to propel drug development and revolutionize the pharma industry?</strong></p>
<p>On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.</p>
<p>Discover new possibilities:</p>
<p>Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.</p>
<p>Why attend?</p>
<ul>
<li><p><strong>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field</strong></p>
</li>
<li><p><strong>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence</strong></p>
</li>
<li><p><strong>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry</strong></p>
</li>
<li><p><strong>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology</strong></p>
</li>
</ul>
<h3>Agenda Day 1: Wednesday, October 25</h3>
<h5><strong>10:00 - 10:40 The Echo® MS system, a high throughout mass spectrometry, Revolution to accelerate hit finding and drug discovery</strong></h5>
<ul>
<li>Celine Legros and Dany Jeanne Dit Fouque (Eurofins)</li>
</ul>
<h5><strong>10:40 - 11:20 Qualification of lipid biomarker assays using chromatography with triple-quad mass spectrometry</strong></h5>
<ul>
<li>Freddy Oosterbring (Ardena)</li>
</ul>
<h5><strong>11:20 - 11:30</strong> Break</h5>
<h5><strong>11:30 - 12:10 Mass spectrometry, a useful aid in Alzheimer´s disease diagnosis</strong></h5>
<ul>
<li>Jose Antonio Allué (Araclon)</li>
</ul>
<h5><strong>12:10 - 12:50 LC-MS to analyze oligonucleotides: a tool for the characterization of new biotherapeutics</strong></h5>
<ul>
<li>Margalida Artigues (IQS)</li>
</ul>
<h5><strong>12:50 - 13:00 Final notes</strong></h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)</p>
</blockquote>
<blockquote>
<p>Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)</p>
</blockquote>
<blockquote>
<p>Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)</p>
</blockquote>
<blockquote>
<p>Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)</p>
</blockquote>
<blockquote>
<p>Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)</p>
</blockquote>
<blockquote>
<p>Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)</p>
</blockquote>
<blockquote>
<p>Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)</p>
</blockquote>
<blockquote>
<p>Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)</p>
</blockquote>
<blockquote>
<p>Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.</p>
</blockquote>


Pharma conclave 2023 (Day 1)

Interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work.

LCMS webinars focusing on LC/HRMS - page 34